(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(amc 2024-05-08)
Expected move: +/- 5.50%
@ $25.78
发出时间: 15 Feb 2024 @ 04:32
回报率: -33.86%
上一信号: Feb 15 - 02:10
上一信号:
回报率: 0.72 %
Live Chart Being Loaded With Signals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders...
Stats | |
---|---|
今日成交量 | 1.12M |
平均成交量 | 1.81M |
市值 | 2.82B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $0.170 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -46.08 |
ATR14 | $0.0130 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Schneyer Mark C. | Buy | 6 814 | Common Stock |
2024-05-02 | Schneyer Mark C. | Sell | 3 503 | Common Stock |
2024-05-01 | Schneyer Mark C. | Sell | 6 814 | Restricted Stock Units |
2024-05-01 | Teehan Brendan | Buy | 6 814 | Common Stock |
2024-05-02 | Teehan Brendan | Sell | 3 477 | Common Stock |
INSIDER POWER |
---|
27.63 |
Last 98 transactions |
Buy: 1 140 321 | Sell: 756 729 |
音量 相关性
ACADIA Pharmaceuticals 相关性 - 货币/商品
ACADIA Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $726.44M |
毛利润: | $680.71M (93.70 %) |
EPS: | $-0.370 |
FY | 2023 |
营收: | $726.44M |
毛利润: | $680.71M (93.70 %) |
EPS: | $-0.370 |
FY | 2022 |
营收: | $517.24M |
毛利润: | $507.07M (98.03 %) |
EPS: | $-1.340 |
FY | 2021 |
营收: | $484.15M |
毛利润: | $465.00M (96.05 %) |
EPS: | $-1.067 |
Financial Reports:
No articles found.
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。